Bagsværd, Denmark, 22 April 2015 - At Novo Nordisk's Annual General Meeting on 19 March 2015, it was decided to reduce the company's B share capital from DKK 422,512,800 to DKK 412,512,800 by cancellation of part of the company's portfolio of own B shares at a nominal value of DKK 10,000,000 divided into 50,000,000 B shares of DKK 0.20 each.

Further information

Media:    
Anne Margrethe Hauge +45 3079 3450 amhg@novonordisk.com
 

Investors:
   
Kasper Roseeuw Poulsen +45 3079 4303 krop@novonordisk.com:
mailto:krop@novonordisk.com
Daniel Bohsen +45 3079 6376 dabo@novonordisk.com:
mailto:dabo@novonordisk.com
Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com:
mailto:mrz@novonordisk.com
Frank Daniel Mersebach (US) +1 609 235 8567 fdni@novonordisk.com:
mailto:fdni@novonordisk.com

Company announcement No 27 / 2015


Company announcement no 27 / 2015:
http://hugin.info/2013/R/1913419/683321.pdf



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire

HUG#1913419